Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Acute myeloid leukaemia, drawn from the whole corpus: 170 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
6 medicines on record are linked to one of the types below rather than to Acute myeloid leukaemia itself. Grouped by the type that holds them; each list opens that type's own page.
TP53-mutant AML: no drug class has yet improved survival, so it is the priority for new mechanisms.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Targets · KRAS roadmap.
Older patients.
TP53-mutated and complex-karyotype AML: no class has improved survival; magrolimab (CD47) failed in phase 3 trials in AML, and eprenetapopt (p53 reactivator) in a phase 3 trial in TP53-mutated MDS.
Relapse after allogeneic transplant is the main way treatment fails; which maintenance (FLT3, menin, azacitidine) helps whom is unresolved.
Background: MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
Menin-inhibitor resistance through MEN1 mutations appears within months in a third of relapsing patients; combinations and next-generation inhibitors are needed.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Infections and low blood counts early in venetoclax-based therapy are the main risk in the very old; optimal venetoclax duration is untested in randomised trials.
MRD thresholds and assays are not harmonised across labs, and CHIP-associated mutations confound NGS MRD.
Background: MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
Whether triplets (menin or FLT3 inhibitor + venetoclax + HMA) improve survival over doublets, and at what toxicity, awaits phase 3.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Access: rapid genomics within 72 hours and menin/FLT3 inhibitors are unavailable in most low- and middle-income settings.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 95 changes by month →FDA orphan drug designation of cantrixil for acute myeloid leukaemia, sponsor Vivesto AB
When this page itself was last checked or edited.
FDA orphan drug designation for acute myeloid leukaemia, granted to SillaJen Inc. for a small-molecule TTK and PLK1 dual inhibitor (the record does not print the code BAL0891)
With venetoclax in newly diagnosed unfit AML
FDA approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)